A phase II study (NCI9775) of sapanisertib (MLN0128/TAK-228) in relapsed and/or refractory acute lymphoblastic leukemia (ALL): Interim analysis.

Aref Al-Kali,Ibrahim Aldoss,Carrie Strand,Bijal D. Shah,Jonathan Webster,Bhavana Bhatnagar,Mojtaba Akhtari,L. Austin Doyle,Scott H. Kaufmann

A phase II study (NCI9775) of sapanisertib (MLN0128/TAK-228) in relapsed and/or refractory acute lymphoblastic leukemia (ALL): Interim analysis.

2019

Aref Al-Kali
Ibrahim Aldoss
Carrie Strand
Bijal D. Shah
Jonathan Webster
Bhavana Bhatnagar
Mojtaba Akhtari
L. Austin Doyle
Scott H. Kaufmann

e18506Background: Sapanisertib (SAP) is an oral small molecule dual mTOR complex 1 and 2 (TORC1/2) inhibitor that showed activity in lymphoid neoplasms. It blocks a feedback loop involving mTORC2 a...

Keywords:

Pathology
Refractory
mTORC2
Small molecule
Interim analysis
Phases of clinical research
Lymphoblastic Leukemia
Cancer research
MTOR complex
Sapanisertib
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations